Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting | ||
By: PR Newswire Association LLC. - 10 Apr 2024 | Back to overview list |
|
KRAKOW, Poland, April 10, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, presents preclinical data from its synthetic lethality pipeline, RVU120, and MEN1703 (SEL24) at the 2024 AACR Annual Meeting, April 5-10 in San Diego, California. "We are excited to present our latest advancements in oncology therapeutics at the AACR Annual Meeting this year. Strong preclinical data from our two lead synthetic lethality programs – PRMT5 and WRN – are encouraging as we make progress toward the identification of competitive clinical candidates," said Krzysztof Brzózka, Ph.D., Chief Scientific Officer of Ryvu Therapeutics. Dr. Brzózka added, "We are also proud of our ONCO Prime target discovery platform, which recently received a significant grant from the Polish Agency for Enterprise Development, giving validation and financial support to our innovative drug discovery efforts. At AACR, we present promising data in KRAS-mutant patient-derived colorectal cancer cells, where the ONCO Prime platform has identified promising novel drug targets. With these initial data, we continue to expand the platform's potential to discover novel anticancer targets across various tumor types." The ONCO Prime target discovery platform aims to identify novel drug targets based on patient-derived primary cell cultures, omics characterization, and functional assays. It already supports preclinical development of Ryvu programs, including PRMT5 and WRN. In March 2024, the Polish Agency for Enterprise Development (PARP) recommended awarding a PLN 26 million (approx. USD 6.6 million) grant to Ryvu to cover five years of ONCO Prime research activities retroactive to May 2023. The ONCO Prime platform covers a broad spectrum of tumor types, and data from colorectal cancer are presented in AACR Poster No. 4684, 'A comprehensive platform for identification of KRAS-specific synthetic lethal targets using patient-derived cells.' AACR 2024 Poster highlights: Abstract Title: 'Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP-deleted cancers.'
Abstract Title: 'Discovery of WRN inhibitors as targeted therapy in the treatment of microsatellite unstable (MSI-H) tumors.'
Abstract Title: 'A comprehensive platform for identification of KRAS-specific synthetic lethal targets using patient-derived cells.'
Abstract Title: 'Combination JAK1/2 and CDK8/19 inhibition demonstrates enhanced efficacy in myeloproliferative neoplasms.'
Abstract Title: 'MEN1703/SEL24 exhibits promising antitumoral activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.'
Posters are available on https://ryvu.com/our-research/. About Ryvu Therapeutics Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small-molecule therapies that address emerging targets in oncology. Internally discovered pipeline candidates use diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, and immuno-oncology targets. Ryvu's most advanced programs include RVU120, a selective CDK8/CDK19 kinase inhibitor with the potential to treat hematological malignancies and solid tumors, currently in Phase II development (i) as a monotherapy for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) and high-risk myelodysplastic syndromes (HR-MDS) as well as (ii) in combination with venetoclax for the treatment of patients with r/r AML. Another clinical program, SEL24 (MEN1703), is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group. Ryvu Therapeutics has signed multiple partnering and licensing deals with global companies, including BioNTech and Exelixis. The Company was founded in 2007 and is headquartered in Kraków, Poland. Ryvu is listed on the Warsaw Stock Exchange and is a component of the mWIG40 index. For more information, please see www.ryvu.com.
View original content:https://www.prnewswire.com/news-releases/ryvu-therapeutics-presents-preclinical-data-on-rvu120-and-synthetic-lethality-programs-at-the-2024-aacr-annual-meeting-302112710.html SOURCE Ryvu Therapeutics |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |